English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

BackgroundMajor depressive disorder (MDD) is a common and dis-abling psychiatric condition. Antidepressants are cur-rently the mainstay of treatment for depression;however, almost two thirds of patients will fail toachieve remission with initial treatment, as a result, arange of augmentation and combination strategies havebeen used [1].Materials and methodsMajor depressive disorder (MDD) is a common and dis-abling psychiatric condition. Antidepressants are cur-rently the mainstay of treatment for depression;however, almost two thirds of patients will fail toachieve remission with initial treatment, as a result, arange of augmentation and combination strategies havebeen used [1].ResultsMood stabilizers are used in 14% of the sample with apredominancy in the female gender (85.7%), a globalaverage age 50.6 ± 12.2 years. Regarding personal psy-chiatric background, there’s an absence of these in thefirst place (64.3%), followed by the presence of previousdepressive episodes (21.4%) and dysthymic disorder(7.1%). In none of these cases there was toxic abuse.There is a predominancy in the absence of previouspsychiatric hospitalisations (64.3%).The frequencies of use of mood stabilizers was: topira-mate in the first place (50%) followed by lithium, carba-mazepine and pregabaline (14.28% each of them), in thelast place lamotrigine (7.1%). The average dose was900 mg/d for carbamazepine, 600 mg/d for lithium,300 mg/d for pregabaline,128.5 mg/d for topiramateand 100 mg/d for lamotrigine.ConclusionsIn our sample the frequency of use of lithium is similarto the registered for the several antiepiletics (lithium,carbamazepine and pregabaline: 14.28% each one). How-ever, lithium addition is recommended as a first choicefor depressed patients who do not respond to therapywith conventional antidepressants [2].

Use of mood stabilizer drugs in the treatment of major depressive dissorder in an outpatient mental health center